Ask AI

CCO Independent Highlights of the 2025 World Conference on Lung Cancer *

Enhance your understanding of novel agents and therapeutic strategies for patients with lung cancers based on data recently presented at the WCLC 2025 and gain expert perspectives on their optimal integration into practice to improve clinical outcomes through certified Medical Minute modules, downloadable capsule summaries, an expert-written ClinicalThought commentary, and a podcast.

Share

Program Content

3 Capsule Summaries

Activities

IMforte Safety Analysis
IMforte: Expanded Safety Analysis of Lurbinectedin + Atezolizumab vs Atezolizumab as First-line Maintenance Therapy in ES-SCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: November 13, 2025

FLAURA2 Final OS
FLAURA2: Final Overall Survival of First-line Osimertinib ± Platinum-Based Chemotherapy in EGFR-Mutated Advanced NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: November 13, 2025

Beamion LUNG 1 Brain Mets
Beamion LUNG-1: Phase Ib Study of Zongertinib in Patients With Previously Treated HER2-Mutant NSCLC and Baseline Brain Metastases
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: November 13, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Jazz Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc.

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.